临床分离大肠埃希菌的耐药性分析  

Analysis of drug resistance of Escherichia coli

作　　者：兰全学[1] 张韶华[1] 朱子犁[1] 李迎慧[1] 饶健[1] 唐屹君[1] 谭丽[1] 杨荣兴[1] 

机构地区：[1]广东省深圳市疾病预防控制中心,广东深圳518020

出　　处：《中国卫生检验杂志》2009年第10期2332-2333,共2页Chinese Journal of Health Laboratory Technology

摘　　要：目的:分析深圳市2009年上半年分离的大肠埃希菌对抗菌药物的耐药性,提供耐药监测数据和指导临床用药。方法:纸片扩散法确证产ESBLs菌株,采用WHONET 5.4软件分析药物敏感性试验结果。结果:43.2%菌株产ESBLs,大肠埃希菌对美罗培南、亚胺培南、阿米卡星、哌拉西林/他唑巴坦敏感率超过90%。对氨苄西林、哌拉西林、复方新诺明、头孢呋辛酯、头孢呋辛钠、氨苄西林/舒巴坦和头孢唑林耐药率超过50%。结论:深圳地区大肠埃希菌对部分常用抗菌药物耐药性严重,应加强耐药性监测,临床要注意合理用药。Objective： To analyze drug resistance of Escherichia coli in the first half of 2009 in Shenzhen to provide drug resistance surveillance data and references for the rational use of drugs. Methods： ESBLs was determined by the disk diffusion method. WHONET 5.4 was employed to analyze the drug resistance. Results ：43.2% of Escherichia coli procedued ESBLs. The sensitive rate of meropenem, imipenem, amikacin and piperacillin - tazobactam was over 90%. The resistance rate of ampicillin, piperacillin, trimethoprim - sulphamethoxazole, cefuroxime axetil, Cefuroxime Sodium, ampicillin - salbactam and cefazolin was over 50%. Conclusion： Drug resistance of Escherichia coli is serious in Shenzhen. Resistance surveillance should be empha- sized. Antibiotics should be used rationally.

关 键 词：大肠埃希菌 抗菌药物 耐药性 

分 类 号：R378.2[医药卫生—病原生物学]